Multiple Myeloma (MM) is a cancer characterized by malignant clonal plasma cells accumulating in the bone marrow. In addition to established treatment with proteasome inhibitors, histone deacetylase inhibitors have recently been approved by the FDA as a complementary treatment strategy. Panobinostat is the first histone deacetylase inhibitor which is already used in clinical MM treatment. However, its exact mechanism of action on chromatin level is still unkonwn.
My master's project aims to contribute to the discovery of differentially regulated genes during Panobinostat treatment. I will study the impact of Panobinostat treatment on histone modifications H3K4me1 and H3K27ac in MM cell lines. These histone modifications are observed in the context of active enhancers. Using ChIPseq, we can complement existing ATACseq and mRNAseq data and investigate the response of different MM cell lines on chromatin level towards Panobinostat. In addition, I will perform scRNAseq to find heterogeneous responses of subpopulations within one cell line.
- since October 2016: Master's thesis in the Research Group Genome Organization and Function (PD Dr. Karsten Rippe) at the German Cancer Research Center (DKFZ), Heidelberg
- since April 2014: Master studies in Molecular Biotechnology with the major Drug Design at Ruprecht-Karls University, Heidelberg
- April 2013 - October 2013: Bachelor's thesis in the CENT lab (Dr. Mohamed ElSayed) at University of Michigan, USA
- October 2010 - December 2013: Bachelor studies in Molecular and Applied Biotechnology at RWTH Aachen Universiyt, Aachen
DKFZ & BioQuant Center
Research Group Genome Organization & Function
Im Neuenheimer Feld 267-BQ24
BioQuant room 641
Fax: +49 6221 54 51487
e-mail: l.dressler (at) stud.uni-heidelberg.de